Geographic Variation in the Susceptibilities of Invasive Isolates of
            <i>Candida glabrata</i>
            to Seven Systemically Active Antifungal Agents: a Global Assessment from the ARTEMIS Antifungal Surveillance Program Conducted in 2001 and 2002

Pfaller, Michael A.; Messer, S. A.; Boyken, L.; Tendolkar, S.; Hollis, Richard J.; Diekema, Daniel J.

doi:10.1128/jcm.42.7.3142-3146.2004

Cited by 166 publications

(123 citation statements)

References 39 publications

Supporting

Mentioning

109

Contrasting

Unclassified

Order By: Relevance

“…VOR resistance has been reported to emerge recently under VOR treatment from 0.3-10 % in different studies. Since frequent use of VOR was reported to be related to both probable and possible Aspergillus infections [35][36][37]. Either L-AmB or CAS is recommended for the treatment of fungemia caused by azole-resitant Candida species.…”

Section: Discussionmentioning

confidence: 99%

Novel Antifungal Drugs Against Fungal Pathogens: Do They Provide Promising Results for Treatment?

Gedık

Şimşek

Yıldırmak

et al. 2014

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

The febrile neutropenia episodes of hematological patients and their outcomes were evaluated with respect to fungal pathogens and antifungal therapy in this retrospective study. All patients, who were older than 14 years of age and developed at least one neutropenic episode after chemotherapy due to hematological cancer from November 2010 to November 2012, were included into the study. We retrospectively collected demographic, treatment, and survival data of 126 patients with neutropenia and their 282 febrile episodes. The mean Multinational Association for Supportive Care in Cancer score was 17.18 ± 8.27. Systemic antifungal drugs were initiated in 22 patients with 30 culture-proven invasive fungal infections (IFIs), 25 attacks of 19 patients with probable invasive pulmonary aspergillosis (IPA), 42 attacks of 38 patients with possible IPA, and 31 attacks of 30 patients with suspected IFI. Voriconazole (VOR), caspofungin and liposomal amphotericin B were used to treat 72 episodes of 65 patients, 45 episodes of 37 patients and 34 episodes of 32 patients as a first-line therapy, respectively. Unfavorable conditions of our hematology ward are thought to increase the number of cases with invasive pulmonary aspergillosis and VOR use. It should be taken into consideration that increased systemic and per oral VOR usage predisposes patients to colonization and infection with azole-resistant fungal strains. Catheters should be removed in cases where patients' conditions are convenient to remove it. Acute myeloblastic leukemia cases that are more likely to develop invasive fungal infections should be monitored closely for early diagnosis and timely initiation of antifungal drugs which directly correlates with survival rates.

show abstract

Section: Discussionmentioning

confidence: 99%

Novel Antifungal Drugs Against Fungal Pathogens: Do They Provide Promising Results for Treatment?

Gedık

Şimşek

Yıldırmak

et al. 2014

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

show abstract

“…Non-albicans Candida species particularly C. krusei and C. glabrata have recently emerged as important causes of [5,8,10,22]. They may be intrinsically resistant to fluconazole, but they are very susceptible to amphotericin-B and the new extended spectrum triazoles such as voriconazole and posaconazole [9,22,26]. The frequency of non-albicans Candida species as causes of bloodstream isolates and their susceptibilities to fluconazole, vary considerably among different countries worldwide [8,17,26,27].…”

Section: Discussionmentioning

confidence: 99%

“…They may be intrinsically resistant to fluconazole, but they are very susceptible to amphotericin-B and the new extended spectrum triazoles such as voriconazole and posaconazole [9,22,26]. The frequency of non-albicans Candida species as causes of bloodstream isolates and their susceptibilities to fluconazole, vary considerably among different countries worldwide [8,17,26,27]. Fungaemia, due to these organisms, carries high mortality rates in immunocompromised individuals, especially in patients with leukaemia, solid tumors and hepatic disorders [8,15,17,21,26,27].…”

Section: Discussionmentioning

confidence: 99%

“…It is most helpful in dealing with severe and invasive fungal infections due to non-albicans species of Candida [9,10,16]. Especially in patients treated with azole antifungal agents, the possibility of microbiological resistance should be taken into consideration [9][10][11]16,26,27]. Azole resistance for C. albicans has been reported in patients with HIV infection and in patients with invasive candidiasis [9][10][11]16].…”

Section: Discussionmentioning

confidence: 99%

“…The frequency of non-albicans Candida species as causes of bloodstream isolates and their susceptibilities to fluconazole, vary considerably among different countries worldwide [8,17,26,27]. Fungaemia, due to these organisms, carries high mortality rates in immunocompromised individuals, especially in patients with leukaemia, solid tumors and hepatic disorders [8,15,17,21,26,27]. As with reports of increased prevalence of non-albicans species of Candida in neutropenic patients, our study showed predominance of non-albicans species particularly C. krusei and C. tropicalis.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Candidaemia in patients with haematological disorders and stem cell transplant

Al-Anazi

Al-Jasser

2006

Libyan Journal of Medicine

View full text Add to dashboard Cite

The incidence of non-albicans species of Candida has recently increased, especially in patients with malignant haematological disorders receiving fluconazole prophylaxis. A retrospective study of patients who developed candidaemia at Riyadh Armed Forces Hospital between January 1992 and December 2002 was carried out. Thirty one episodes of candidaemia occurred in 27 patients with a variety of haematological disorders. Twenty-four episodes were caused by non-albicans species of Candida and only 7 episodes were caused by C.albicans. The most frequent underlying haematological disorders were acute myeloid leukaemia (AML) followed by acute lymphoblastic leukaemia (ALL). The main predisposing factors for the development of candidaemia were: broad spectrum antibiotics, central venous catheters, neutropenia, cytotoxic chemotherapy, coexisting bacterial infections, steroid therapy, relapsing or untreated primary disease and fluconazole prophylaxis.Eight episodes were complicated by chronic disseminated candi-

show abstract

Acquired multidrug‐resistant Candida glabrata in Australia: a case report

Koch

Harding

Hughes

2019

Pharmacy Practice and Res

View full text Add to dashboard Cite

BackgroundCandida glabrata is the second most common cause of candidaemia in Australia, and echinocandins remain the first‐line choice for empirical treatment. There have been increasing reports of multidrug‐resistant (MDR) C. glabrata worldwide. To date, there have been no documented cases of MDR C. glabrata in Australia. This paper describes a case of C. glabrata resistant to azole antifungals and echinocandins in Australia.Clinical detailsA 47‐year‐old male was admitted for management of acute graft‐versus‐host disease (GVHD) of the gastrointestinal tract on Day 129 after allogeneic haematopoietic stem cell transplant for chronic lymphocytic leukaemia. On Day 38 of admission, the patient developed C. glabrata candidaemia that was susceptible to echinocandins but resistant to azole antifungals. The patient received a 17‐day course of intravenous (IV) caspofungin with subsequent negative blood cultures. However, on Day 67, the patient again developed C. glabrata candidaemia that now exhibited resistance to echinocandins and azole antifungals.OutcomesThe patient was commenced on liposomal amphotericin B (3 mg/kg, IV, daily) by the infectious diseases unit. A literature search by the pharmacist prompted a recommendation of a dose increase to 5 mg/kg, IV, daily given this isolate had a high minimum inhibitory concentration of 1 microgram/mL. Liposomal amphotericin B continued for 14 days with no further positive blood cultures. Unfortunately the patient died on Day 92 of admission secondary to severe treatment‐refractory GVHD.ConclusionThis case highlights a case of MDR C. glabrata in Australia, which is of concern given the recommended empirical use of echinocandins for candidaemia.

show abstract

Geographic Variation in the Susceptibilities of Invasive Isolates of Candida glabrata to Seven Systemically Active Antifungal Agents: a Global Assessment from the ARTEMIS Antifungal Surveillance Program Conducted in 2001 and 2002

Cited by 166 publications

References 39 publications

Novel Antifungal Drugs Against Fungal Pathogens: Do They Provide Promising Results for Treatment?

Novel Antifungal Drugs Against Fungal Pathogens: Do They Provide Promising Results for Treatment?

Candidaemia in patients with haematological disorders and stem cell transplant

Acquired multidrug‐resistant Candida glabrata in Australia: a case report

Contact Info

Product

Resources

About